Publications

Author Title [ Year(Asc)]
Filters: First Letter Of Last Name is S  [Clear All Filters]
2015
Chatr-Aryamontri A, Breitkreutz B-J, Oughtred R, Boucher L, Heinicke S, Chen D, Stark C, Breitkreutz A, Kolas N, O'Donnell L et al..  2015.  The BioGRID interaction database: 2015 update. Nucleic Acids Res. 43(Database issue):D470-8.
Chatr-Aryamontri A, Breitkreutz B-J, Oughtred R, Boucher L, Heinicke S, Chen D, Stark C, Breitkreutz A, Kolas N, O'Donnell L et al..  2015.  The BioGRID interaction database: 2015 update. Nucleic Acids Res. 43(Database issue):D470-8.
Yuan C, Smith WL.  2015.  A Cyclooxygenase-2-dependent Prostaglandin E2 Biosynthetic System in the Golgi Apparatus. J Biol Chem. 290(9):5606-20.
Griffin JL, Wang X, Stanley E.  2015.  Does our gut microbiome predict cardiovascular risk? A review of the evidence from metabolomics. Circ Cardiovasc Genet. 8(1):187-91.
Prilutsky D, Kho AT, Palmer NP, Bhakar AL, Smedemark-Margulies N, Kong SWon, Margulies DM, Bear MF, Kohane IS.  2015.  Gene expression analysis in Fmr1KO mice identifies an immunological signature in brain tissue and mGluR5-related signaling in primary neuronal cultures.. Mol Autism. 6:66.
Xiang Y, Cheng J, Wang D, Hu X, Xie Y, Stitham J, Atteya G, Du J, Tang WHo, Lee SHee et al..  2015.  Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood. 125(22):3377-87.
Xiang Y, Cheng J, Wang D, Hu X, Xie Y, Stitham J, Atteya G, Du J, Tang WHo, Lee SHee et al..  2015.  Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood. 125(22):3377-87.
Mazaleuskaya LL, Sangkuhl K, Thorn CF, FitzGerald GA, Altman RB, Klein TE.  2015.  PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 25(8):416-26.
Greene CS, Krishnan A, Wong AK, Ricciotti E, Zelaya RA, Himmelstein DS, Zhang R, Hartmann BM, Zaslavsky E, Sealfon SC et al..  2015.  Understanding multicellular function and disease with human tissue-specific networks. Nat Genet. 47(6):569-76.
2014
Tang WHo, Stitham J, Jin Y, Liu R, Lee SHee, Du J, Atteya G, Gleim S, Spollett G, Martin K et al..  2014.  Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation. 129(15):1598-609.
Tang WHo, Stitham J, Jin Y, Liu R, Lee SHee, Du J, Atteya G, Gleim S, Spollett G, Martin K et al..  2014.  Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation. 129(15):1598-609.
Jiang Y, Djuric Z, Sen A, Ren J, Kuklev D, Waters I, Zhao L, Uhlson CL, Hong YH, Murphy RC et al..  2014.  Biomarkers for personalizing omega-3 fatty acid dosing. Cancer Prev Res (Phila). 7(10):1011-22.
Jiang Y, Djuric Z, Sen A, Ren J, Kuklev D, Waters I, Zhao L, Uhlson CL, Hong YH, Murphy RC et al..  2014.  Biomarkers for personalizing omega-3 fatty acid dosing. Cancer Prev Res (Phila). 7(10):1011-22.
Vanichakarn P, Hwa J, Stitham J.  2014.  Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies. Curr Mol Med. 14(7):849-79.
Stitham J, Vanichakarn P, Ying L, Hwa J.  2014.  Cardiovascular pharmacogenetics of anti-thrombotic agents and non-steroidal anti-inflammatory drugs. Curr Mol Med. 14(7):909-31.
Sahu RP, Ocana JA, Harrison KA, Ferracini M, Touloukian CE, Al-Hassani M, Sun L, Loesch M, Murphy RC, Althouse SK et al..  2014.  Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res. 74(23):7069-78.
Sahu RP, Ocana JA, Harrison KA, Ferracini M, Touloukian CE, Al-Hassani M, Sun L, Loesch M, Murphy RC, Althouse SK et al..  2014.  Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res. 74(23):7069-78.
Sahu RP, Ocana JA, Harrison KA, Ferracini M, Touloukian CE, Al-Hassani M, Sun L, Loesch M, Murphy RC, Althouse SK et al..  2014.  Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res. 74(23):7069-78.
Chang S-H, Elemento O, Zhang J, Zhuang ZW, Simons M, Hla T.  2014.  ELAVL1 regulates alternative splicing of eIF4E transporter to promote postnatal angiogenesis. Proc Natl Acad Sci U S A. 111(51):18309-14.
Keramati AR, Fathzadeh M, Go G-W, Singh R, Choi M, Faramarzi S, Mane S, Kasaei M, Sarajzadeh-Fard K, Hwa J et al..  2014.  A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med. 370(20):1909-19.

Pages